Genzyme to buy back rights Genzyme Corp. of Cambridge, Mass., agreed Thursday to buy back the sales and marketing rights for Synvisc, a pain treatment for people suffering from osteoarthritis of the knee, from Wyeth Pharmaceuticals of Collegeville, Pa. 
Is this a piece of news regarding world politics, sports, business, or science and technology? 